Lokavant Receives $8M Investment from Mitsui & Co.
Company intends to expand AI and predictive clinical trial intelligence throughout the Asia-Pacific region.
Lokavant announced that it has received an $8 million strategic investment from Mitsui & Co. to expand its AI-optimized platform across the Asia-Pacific region. As part of the investment, the company intends to open a new regional headquarters in Tokyo. According to a company press release, the investment is the result of a yearlong effort between the two companies, with Mitsui pledging to provide operational support, including business development, staffing, and product localization to expand Lokavant’s range in the region.
“Lokavant’s platform has driven significant value to pharmaceutical sponsors and CROs on global clinical trials, and with exceptional validation of the platform in Japan, it is a natural next step to launch Lokavant Asia,” said Rohit Nambisan, CEO, co-founder, Lokavant. “With a distinguished track record in international business and a rapidly growing reputation in life sciences innovation, Mitsui & Co is the ideal strategic partner for the creation of Lokavant AsiaPac.”
Reference: Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific. Business Wire. October 3, 2023. Accessed October 3, 2023. https://www.businesswire.com/news/home/20231003076721/en/Lokavant-Announces-8M-Strategic-Investment-from-Mitsui-Co.-to-Expand-AI-and-Predictive-Clinical-Trial-Intelligence-into-Asia-Pacific
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
